Otsuka Holdings Co., Ltd. in 2 stories

The narratives 4578.T currently appears in, with its side and exposure in each.

0 stories

No bull-side stories for 4578.T yet.

2 stories

America Imports the World's Drug Prices
4578.T in “America Imports the World's Drug Prices”
StableExposure: not rated yet
US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Otsuka's premium-priced CNS and rare-disease portfolio, including Rexulti and Jynarque, is exposed to lower US prices and tougher launch sequencing decisions.
The Patent Cliff Sparks a Biotech Land Grab
4578.T in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yet
Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Approaching exclusivity losses in core neuropsychiatric products leave Otsuka dependent on successful launches, licensing and acquisitions to replace concentrated revenue.

2 stories

America Imports the World's Drug Prices
4578.T in “America Imports the World's Drug Prices”
StableExposure: not rated yet
US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Otsuka's premium-priced CNS and rare-disease portfolio, including Rexulti and Jynarque, is exposed to lower US prices and tougher launch sequencing decisions.
The Patent Cliff Sparks a Biotech Land Grab
4578.T in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yet
Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Approaching exclusivity losses in core neuropsychiatric products leave Otsuka dependent on successful launches, licensing and acquisitions to replace concentrated revenue.